Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency
- 1 November 2017
- journal article
- case report
- Published by Elsevier in Antiviral Research
- Vol. 147, 58-66
Abstract
No abstract availableKeywords
Funding Information
- Centers for Disease Control and Prevention
- Oulu University Hospital VTR (K74809)
- Finnish Medical Foundation
- Helsinki University Hospital Research (TYH2016131)
This publication has 42 references indexed in Scilit:
- Nitazoxanide May Modify the Course of Progressive Multifocal LeukoencephalopathyJournal of Clinical Immunology, 2017
- Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiencyClinical Microbiology and Infection, 2014
- Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca2+ storesVirology, 2014
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational LevelJournal of Biological Chemistry, 2009
- Thiazolides: a new class of antiviral drugsExpert Opinion on Drug Metabolism & Toxicology, 2009
- Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolidesWorld Journal of Gastroenterology, 2009
- Peginterferon and Ribavirin for Chronic Hepatitis CNew England Journal of Medicine, 2006
- Nitazoxanide: pharmacokinetics and metabolism in manInt. Journal of Clinical Pharmacology and Therapeutics, 2000
- Fetal rubella pathologyThe Journal of Pediatrics, 1966